Found 4 results
Filters: Author is Q. Guo  [Clear All Filters]
L. P. Ren, Xian, Y. S., Diao, D. M., Chen, Y., Guo, Q., and Dang, C. X., Further evidence for the contribution of the BRCA1-interacting protein-terminal helicase 1 (BRIP1) gene in breast cancer susceptibility, vol. 12, pp. 5793-5801, 2013.
J. Zhu, Wei, R. L., Pi, Y. L., and Guo, Q., Significance of Bcl10 gene mutations in the clinical diagnosis of MALT-type ocular adnexal lymphoma in the Chinese population, vol. 12, pp. 1194-1204, 2013.
Coupland SE (2004). Lymphoproliferative lesions of the ocular adnexa. Differential diagnostic guidelines. Ophthalmologe 101: 197-215. PMid:15046030   Du MQ (2011). MALT lymphoma: many roads lead to nuclear factor-kappab activation. Histopathology 58: 26-38. PMid:21261681   Du MQ, Peng H, Liu H, Hamoudi RA, et al. (2000). BCL10 gene mutation in lymphoma. Blood 95: 3885-3890. PMid:10845924   Garrison JB, Samuel T and Reed JC (2009). TRAF2-binding BIR1 domain of c-IAP2/MALT1 fusion protein is essential for activation of NF-kappaB. Oncogene 28: 1584-1593. PMid:19234489   Hamoudi RA, Appert A, Ye H, Ruskone-Fourmestraux A, et al. (2010). Differential expression of NF-kappaB target genes in MALT lymphoma with and without chromosome translocation: insights into molecular mechanism. Leukemia 24: 1487-1497. PMid:20520640   Hosokawa Y and Seto M (2004). Nuclear factor kappaB activation and antiapoptosis in mucosa-associated lymphoid tissue lymphoma. Int. J. Hematol. 80: 215-223. PMid:15540895   Kingeter LM and Schaefer BC (2010). Malt1 and cIAP2-Malt1 as effectors of NF-kappaB activation: kissing cousins or distant relatives? Cell Signal. 22: 9-22. PMid:19772915 PMCid:2766428   Marcus R (2007). Pathogenesis of MALT lymphoma: implications for risk stratification and therapy. Leuk. Lymphoma 48: 2087-2088. PMid:17990172   McKelvie PA (2010). Ocular adnexal lymphomas: a review. Adv. Anat. Pathol. 17: 251-261. PMid:20574170   Misdraji J, Harris NL, Hasserjian RP, Lauwers GY, et al. (2011). Primary follicular lymphoma of the gastrointestinal tract. Am. J. Surg. Pathol. 35: 1255-1263. PMid:21836483   Prasad S, Ravindran J and Aggarwal BB (2010). NF-kappaB and cancer: how intimate is this relationship. Mol. Cell Biochem. 336: 25-37. PMid:19823771 PMCid:3148942   Rohatiner A, d'Amore F, Coiffier B, Crowther D, et al. (1994). Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann. Oncol. 5: 397-400. PMid:8075046   Rosebeck S, Lucas PC and McAllister-Lucas LM (2011). Protease activity of the API2-MALT1 fusion oncoprotein in MALT lymphoma development and treatment. Future Oncol. 7: 613-617. PMid:21568677 PMCid:3124218   Sagaert X, De Wolf-Peeters C, Noels H and Baens M (2007). The pathogenesis of MALT lymphomas: where do we stand? Leukemia 21: 389-396. PMid:17230229   Sun W and Yang J (2010). Molecular basis of lysophosphatidic acid-induced NF-kappaB activation. Cell Signal. 22: 1799-1803. PMid:20471472 PMCid:2939192   Thieblemont C, Bastion Y, Berger F, Rieux C, et al. (1997). Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J. Clin. Oncol. 15: 1624-1630. PMid:9193362   Willis TG, Jadayel DM, Du MQ, Peng H, et al. (1999). Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 96: 35-45.   Wu CJ and Ashwell JD (2008). NEMO recognition of ubiquitinated Bcl10 is required for T cell receptor-mediated NF-kappaB activation. Proc. Natl. Acad. Sci. U. S. A. 105: 3023-3028. PMid:18287044 PMCid:2268578   Ye H, Gong L, Liu H, Hamoudi RA, et al. (2005). MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression. J. Pathol. 205: 293-301. PMid:15682443   Zhou H, Wertz I, O'Rourke K, Ultsch M, et al. (2004). Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO. Nature 427: 167-171. PMid:14695475